•Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy
•Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study
•Oral Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Intestinal Inflammation
•Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort
•Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis
